Nika Pharmaceuticals completes merger with Nika BioTechnology; increases preferred authorized shares

NIKA PHARMACEUTICALS, INC

Merger effective March 1, 2024; Nika BioTech shareholders receive 1 NKPH share per NIKA share.
Controlling shareholder Dimitar Slavchev Savov owns ~69% of merged entity's common and 100% of Preferred A.
Articles amended to increase authorized Preferred A shares from 10M to 15M, filed March 4, 2024.
Both companies had same board and officers; management unchanged post-merger.
Shareholders approved the merger on February 12, 2024, and the transaction closed as planned.

item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

NIKA PHARMACEUTICALS, INC: Increased authorized Preferred A stock from 10,000,000 to 15,000,000 (effective 2024-03-04).

Change: charter amendment
Effective: 2024-03-04

Exact text from the filing

Pursuant to the terms of the Agreement and Plan of Merger and the approval of the company’s board of directors and shareholders, Nika Pharmaceuticals, Inc. has filed an Amendment to the Articles of Incorporation to increase the number of authorized Preferred A stock from 10,000,000 to 15,000,000, effective as of March 4, 2024 when the amendment was filed with the Colorado Secretary of State.

View on SEC.gov

Browse all governance changes →

NIKA PHARMACEUTICALS, INC filing history →

Source: SEC EDGAR

accession 0001826466-24-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.